

## References

I-130

1. Yuan X, Gavriilaki E, Brodsky R, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. *Haematologica*. 2017;102:466-475.
2. Sasapu A, Cottler-Fox M, Motwani P. Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab. *Baylor University Medical Center Proceedings*. 2017;30:182-183.
3. Tran D, Boucher A, Collette S, et al. Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature. *Case Reports in Transplantation*. 2016;1-4.
4. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol*. 2017;976–86.
5. MICROMEDEX®SOLUTIONS Compendia. 2019. Eculizumab.
6. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. Eculizumab.
7. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
8. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. *Blood*. 2011;6786-6793.
9. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
10. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
11. Soliris® (Eculizumab) [package insert]. Alexion Pharmaceuticals, Inc. Boston, MA. 2007. Revised 06/2019.
12. Ultomiris™ (ravulizumab-cwvz) [package insert]. Alexion Pharmaceuticals, Inc. Boston, MA. 2018. Revised 10/2019.
13. Hayes, Inc. Hayes Prognosis Overview. Ultomiris (Ravulizumab-cwvz) for Paroxysmal Nocturnal Hemoglobinuria. Landsdale, PA: Hayes, Inc.; January 2019.
14. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. *N Engl J Med*. 2019;381(7):614-625.
15. Kulasekararaj A, Hill A, Rottinghaus S, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood*. 2019 Feb 7; 133(6): 540–549.
16. Wook Lee J, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. *Blood*. 2019 Feb 7; 133(6): 530–539.